Glucose metabolism in cardiac hypertrophy and heart failure

DH Tran, ZV Wang - Journal of the American Heart Association, 2019 - Am Heart Assoc
Heart failure is one of the leading causes of death worldwide and has been singled out as
an emerging epidemic. 1, 2 With a 5-year survival rate of 50%, heart failure poses a …

Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes

SC Kolwicz Jr, S Purohit, R Tian - Circulation research, 2013 - Am Heart Assoc
The network for cardiac fuel metabolism contains intricate sets of interacting pathways that
result in both ATP-producing and non–ATP-producing end points for each class of energy …

Myocardial fatty acid metabolism in health and disease

GD Lopaschuk, JR Ussher, CDL Folmes… - Physiological …, 2010 - journals.physiology.org
There is a constant high demand for energy to sustain the continuous contractile activity of
the heart, which is met primarily by the β-oxidation of long-chain fatty acids. The control of …

[HTML][HTML] Targeting fatty acid and carbohydrate oxidation—a novel therapeutic intervention in the ischemic and failing heart

JS Jaswal, W Keung, W Wang, JR Ussher… - … et Biophysica Acta (BBA …, 2011 - Elsevier
Cardiac ischemia and its consequences including heart failure, which itself has emerged as
the leading cause of morbidity and mortality in developed countries are accompanied by …

Glucose metabolism and cardiac hypertrophy

SC Kolwicz Jr, R Tian - Cardiovascular research, 2011 - academic.oup.com
The most notable change in the metabolic profile of hypertrophied hearts is an increased
reliance on glucose with an overall reduced oxidative metabolism, ie a reappearance of the …

Energy metabolism in the normal and failing heart: potential for therapeutic interventions

WC Stanley, MP Chandler - Heart failure reviews, 2002 - Springer
The chronically failing heart has been shown to be metabolically abnormal, in both animal
models and in patients. Little data are available on the rate of myocardial glucose, lactate …

Growth differentiation factor 15, ST2, high‐sensitivity troponin T, and N‐terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection …

R Santhanakrishnan, JPC Chong, TP Ng… - European journal of …, 2012 - Wiley Online Library
Aims Growth differentiation factor 15 (GDF15), ST2, high‐sensitivity troponin T (hsTnT), and
N‐terminal pro brain natriuretic peptide (NT‐proBNP) are biomarkers of distinct mechanisms …

Cardiolipin and apoptosis

JB McMillin, W Dowhan - Biochimica et Biophysica Acta (BBA)-Molecular …, 2002 - Elsevier
Cardiolipin (CL) is recognized to be an essential phospholipid in eukaryotic energy
metabolism so that physiological and pathological perturbations in its synthetic and …

Metabolic manipulation in ischaemic heart disease, a novel approach to treatment

L Lee, J Horowitz, M Frenneaux - European heart journal, 2004 - academic.oup.com
Antianginal drugs that exert their anti-ischaemic effects primarily by altering myocardial
metabolism have recently attracted attention. They have the potential to relieve symptoms in …

First clinical trial with etomoxir in patients with chronic congestive heart failure

S SCHMIDT-SCHWEDA, C HOLUBARSCH - Clinical science, 2000 - portlandpress.com
In the failing human myocardium, both impaired calcium homoeostasis and alterations in the
levels of contractile proteins have been observed, which may be responsible for reduced …